This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
What: GW Pharmaceuticals, a biopharmaceutical company focused on discovering, developing and commercializing innovative therapeutics from its proprietary cannabinoid product platform will visit the NASDAQ MarketSite in Times Square to celebrate its initial public offering (IPO), which occurred today, Wednesday, May 1 on The NASDAQ Stock Market.
In honor of the occasion, Dr. Geoffrey Guy, Chairman and Justin Gover, CEO, will ring the Closing Bell.
Where: NASDAQ MarketSite – 4 Times Square – 43
rd & Broadway – Broadcast Studio
When: Wednesday, May 1, 2013 – 3:45 p.m. to 4:00 p.m. ET
Contact: Kerry F. Kelly (646) 541-9933
Kerry.firstname.lastname@example.orgNASDAQ MarketSite: Jennifer Knapp (212) 401-8916
Jennifer.email@example.comFeed Information: Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Facebook and Twitter: For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
For news tweets, please visit our Twitter page at:
Webcast: A live webcast of the NASDAQ Closing Bell will be available at:
Photos: To obtain a hi-resolution photograph of the Market Close, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About GW Pharmaceuticals: Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 20 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world leading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional cannabinoid product candidates, including two distinct compounds, GWP42004 and GWP42003, in Phase 2 clinical development for Type 2 diabetes and ulcerative colitis, respectively, and at least two additional programs expected to enter Phase 1 and Phase 2 clinical trials in the next 12 months. For further information, please visit
About NASDAQ OMX Group: The inventor of the electronic exchange, The NASDAQ OMX Group, Inc., fuels economies and provides transformative technologies for the entire lifecycle of a trade - from risk management to trade to surveillance to clearing. In the U.S. and Europe, we own and operate 26 markets including 3 clearinghouses and 5 central securities depositories supporting equities, options, fixed income, derivatives, commodities, futures and structured products. Able to process more than 1 million messages per second at sub-55 microsecond average speeds with 99.99% uptime, our technology drives more than 70 marketplaces in 50 developed and emerging countries into the future, powering 1 in 10 of the world's securities transactions. Our award-winning data products and worldwide indexes are the benchmarks in the financial industry. Home to approximately 3,300 listed companies worth $6 trillion in market cap whose innovations shape our world, we give the ideas of tomorrow access to capital today. Welcome to where the world takes a big leap forward, daily. Welcome to the NASDAQ OMX Century. To learn more, visit
www.nasdaqomx.com . Follow us on Facebook (
http://www.facebook.com/NASDAQ ) and Twitter (
http://www.twitter.com/nasdaqomx ). (Symbol: NDAQ and member of S&P 500)